EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study

Thalia Berenice Jacobo-Vargas, Renata Báez-Saldaña iD, Luis Pablo Cruz-Hervert, Teresa Imelda Fortoul, Victor Hugo Ahumada-Topete iD, Odalis Rodríguez-Ganén, Ricardo Stanley Vega-Barrientos

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285541 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Thalia Berenice Jacobo-Vargas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacist in Pharmacology Research Unit and Hospital Pharmacy Department, National Institute of Respiratory Diseases, Mexico City, Mexico. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, HIV Infections, Neutropenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial of first choice in the treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients, particularly in people living with human immunodeficiency virus (HIV). TMP/SMX use entails different adverse effects, and its association with early neutropenia is minimally documented. This study aimed to identify the risk of early neutropenia associated with TMP/SMX use in adults living with HIV in Mexico.

Methods

A prospective cohort study was conducted in TMP/SMX-naïve adults living with HIV admitted to a third-level hospital between August 2019 and March 2020. Socio-demographic, clinical, and laboratory data were collected. According to patients’ diagnostic, if they required treatment or prophylaxis against PCP, medical staff decided to prescribe TMP/SMX, as it is the first-line treatment. The risk of TMP/SMX induced early neutropenia, as well as associated factors were analyzed through a bivariate model and a multivariate Poisson regression model. The strength of association was measured by incidence rate ratio (IRR) with 95% confidence interval.

Results

57 patients were enrolled in the study, of whom 40 patients were in the TMP/SMX treatment-group for treatment or prophylaxis of PCP (204.8 person-years of observation, median 26.5 days) and 17 patients were in the non-treatment group because they did not need the drug for treatment or prophylaxis of PCP (87.0 person-years of observation, median 21 days). The incidence rate of early neutropenia in the TMP/SMX-treatment group versus non-treatment group was 7.81 and 1.15 cases per 100 person-years, respectively. After adjusting for stage 3 of HIV infection and neutrophil count

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, PneumocystisHIV InfectionsNeutropeniaHumansAdultTrimethoprim, Sulfamethoxazole Drug CombinationCohort StudiesHIVProspective StudiesMexicoRetrospective Studies

Substanzen

Trimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Pharmacist in Pharmacology Research Unit and Hospital Pharmacy Department, National Institute of Respiratory Diseases, Mexico City, Mexico.
  • Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, National Autonomous University of Mexico, Mexico City, Mexico.
  • Hospitalization, National Institute of Respiratory Diseases, Mexico City, Mexico.
  • Professor of Orthodontic Department in the Division of Postgraduate Studies and Research, Faculty of Dentistry, National Autonomous University of Mexico, Mexico City, Mexico.
  • Program on Epidemiological and Emerging Risks, National Autonomous University of Mexico, Mexico City, Mexico.
  • School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

ORCID-Profile: Renata Báez-Saldaña, Victor Hugo Ahumada-Topete

Förderung

  • National Council of Science and Technology

Zitieren

APA

Jacobo-Vargas, T. B., Báez-Saldaña, R., Cruz-Hervert, L. P., Fortoul, T. I., Ahumada-Topete, V. H., Rodríguez-Ganén, O., & Vega-Barrientos, R. S. (2023). Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0285541

Vancouver

Jacobo-Vargas TB, Báez-Saldaña R, Cruz-Hervert LP, Fortoul TI, Ahumada-Topete VH, Rodríguez-Ganén O, et al. Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study. PLOS ONE. 2023. doi:10.1371/journal.pone.0285541

BibTeX
@article{JacoboVargas2023,
  author = {Jacobo-Vargas, Thalia Berenice and Báez-Saldaña, Renata and Cruz-Hervert, Luis Pablo and Fortoul, Teresa Imelda and Ahumada-Topete, Victor Hugo and Rodríguez-Ganén, Odalis and Vega-Barrientos, Ricardo Stanley},
  title = {Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285541}
}
Kostenlos starten →